AnaptysBio, Inc. (NASDAQ:ANAB) Receives $39.20 Consensus Price Target from Analysts
Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been given an average recommendation of “Hold” by the five analysts that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month price […]